Great progress has been made in many countries to tackle the HIV epidemic. A newly diagnosed patient with access to the latest antiretroviral therapy (ART) can hope to have a normal life expectancy. Yet, over 30 years since the emergence of the virus, and 28 years since the first World’s AIDS Day, much more needs to done to bring these advances to developing countries and to reach groups at high risk of HIV transmission. One of the biggest barriers to achieving this aim is the stigma that is still rife in many countries.
Seeking a cure for HIVSubscription
Efforts to find a cure for HIV were reinvigorated in 2008 when the case of Timothy Ray Brown showed that a cure is possible. Researchers and pharmaceutical companies are now seeking out the virus in its hiding places in an attempt to eradicate it completely.
Pharmacist Ana Martinez explains how involving pharmacists in HIV clinical trials earned her the highest honour from the International Pharmaceutical Federation.
HIV services need to evolve to meet new needsSubscription
A stronger, less fragmented system of HIV services is needed in order to keep pace with the changing needs of patients.
Limiting HIV resistance must not be neglected in an era where we continue to see breakthroughs in treatment for the infection once labelled a death sentence.
Unanswered questions about proposed PrEP trial Subscription
With 17 new HIV diagnoses made every day in the UK, we need to be bold and ambitious in our approach to HIV prevention — and this must include access to pre-exposure prophylaxis (PrEP) for all who need it.
On this World AIDS Day the National AIDS Trust’s theme is stigma, and there is so much that healthcare workers can do to help to combat stigma from the frontlines. The recently published UK Stigma Index highlighted the real problem in healthcare, with only 58% of people living with HIV feeling well supported by their GP practice, and 13% having heard negative comments ...
The US Food and Drug Administration has requested that a formulation of oxymorphone hydrochloride, marketed as Opana ER, be withdrawn from the market due to abuse, saying that the benefits of the product no longer outweigh the risks.
Reducing the toxicity of antiretroviral drugs, improving prophylaxis and better management of comorbidities have extended life expectancy for people with HIV, study results show.
A Wales-wide study to make the antiretroviral combination treatment Truvada available for pre-exposure prophylaxis (PrEP) against HIV infection has been announced by Vaughan Gething, Welsh health secretary.
People in Scotland at risk of HIV will be able to access pre-exposure prophylaxis (PrEP) treatment on the NHS.